April 25, 2017

Marrone Bio Innovations, Inc. Announces Pricing of Its Common Stock Offering

DAVIS, Calif.--(BUSINESS WIRE)-- Marrone Bio Innovations, Inc. (NASDAQ:MBII or "the Company"), today announced the pricing of its previously announced underwritten public offering. The Company is offering 5,714,286 registered shares of its common stock, par value $0.00001 per share, at a price to the public of $1.40 per share, resulting in gross proceeds of approximately $8.0 million. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 857,143 shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering primarily to for general corporate purposes, which may include operating expenses, working capital to improve and promote its commercially available products, advance product candidates, expand international presence and commercialization, and general capital expenditures. The offering is expected to settle and close on April 28, 2017, subject to the satisfaction or waiver of customary closing conditions.

National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NasdaqCM:NHLD), is acting as sole book-running manager for the offering.

The securities described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-215024), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 6, 2017. A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus may be obtained by contacting the book-running manager at the following address:

National Securities Corporation
410 Park Ave, 14th Floor
New York, NY 10022
Attn: Marguerite Rogers
Telephone: 212-417-8227
Email: prospectusrequest@nationalsecurities.com

A final prospectus supplement describing the terms of the offering will be filed with the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Marrone Bio Innovations, Inc., and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Marrone Bio Innovations, Inc.

Marrone Bio Innovations, Inc. (NASDAQ:MBII or "the Company") strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. The Company's effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. The Company has five products for agriculture on the market (Regalia®, Grandevo®, Venerate®, and Majestene® and Haven™), and also distributes Bio-tam 2.0® for Isagro USA in the western U.S. The Company markets Zequanox® for invasive mussels for water markets. Marrone also has a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations, the Company is dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Examples of such statements include, but are not limited to, statements relating to the completion of the offering, the grant of an over-allotment option and use of proceed from the offering. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including any difficulty in obtaining additional financing to meet the Company's business requirements and service its debt, difficulty in developing, manufacturing, marketing or selling the Company's products, any failure to maintain and further establish relationships with distributors and other partners, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse decisions by regulatory agencies and other third parties and other factors described in the "Risk Factors" section of the prospectus and the Company's most recent Annual Report on Form 10-K.. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations:
Marrone Bio Innovations, Inc.
James Palczynski, 203-682-8229

Source: Marrone Bio Innovations, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Marrone Bio Innovations